Synairgen (LON:SNG) Sets New 1-Year Low at $7.50
Shares of Synairgen plc (LON:SNG) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 7.50 ($0.10) and last traded at GBX 7.75 ($0.10), with a volume of 210202 shares trading hands. The stock had previously closed at GBX 8.88 ($0.12).
Separately, FinnCap reissued a “corporate” rating on shares of Synairgen in a report on Monday, September 30th.
The firm has a market cap of $8.48 million and a price-to-earnings ratio of -2.28. The company has a fifty day moving average price of GBX 9.26 and a 200-day moving average price of GBX 11.63.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Recommended Story: How do investors use RSI to grade stocks?
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.